Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘New GSK’ Still Has Some Convincing To Do

Vaccine And Speciality Medicines The Focus

Executive Summary

Once the consumer health division is spun out in mid-2022, a leaner ‘new GSK’ must set about delivering on its promising pipeline – and proving its skeptics wrong.

You may also be interested in...



New GSK To Leave Flagship HQ After Consumer Health Split

Company follows US office downsizing with similar plans for its global headquarters, once consumer health spin-out is complete in 2022.

Another Activist Investor Joins Calls For GSK Leadership Review

A second activist investor has called for GSK to consider replacing Emma Walmsley as CEO, and has underlined competitive threats to a key pipeline candidate.

‘New GSK’ Should Consider New CEO Too, Says Activist Investor

Elliott Advisors have said more pharma expertise on the board – including a possible new CEO – is the only way for GSK to restore investor confidence.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144599

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel